Document is current
Any future updates will be listed below
-
Authors
Mecklenbrauck, Rabea https://orcid.org/0009-0005-9374-300X
Villaverde Ramiro, Angela https://orcid.org/0000-0002-7337-7218
Sträng, Eric
Gabdoulline, Razif
Martinez Elicegui, Javier https://orcid.org/0000-0001-5294-6162
Sobas, Marta
Pleyer, Lisa
Turki, Amin
Voso, Maria Teresa https://orcid.org/0000-0002-6164-4761
Benner, Axel
Hernández-Sánchez, Alberto https://orcid.org/0000-0002-6601-3096
Tettero, Jesse M. https://orcid.org/0000-0002-0811-0824
Tur Gimenez, Laura
Metzeler, Klaus H. https://orcid.org/0000-0003-3920-7490
Oñate, Guadalupe https://orcid.org/0000-0003-2180-2371
Lehmann, Sören
Huntly, Brian JP
Thomas, Ian
Thol, Felicitas R. https://orcid.org/0000-0001-5848-6152
Heidel, Florian H. https://orcid.org/0000-0003-2438-1955
Valk, Peter JM https://orcid.org/0000-0002-8857-9461
Döhner, Konstanze
Haferlach, Torsten
Mills, Kenneth I. https://orcid.org/0000-0002-6362-4481
Döhner, Hartmut https://orcid.org/0000-0003-2116-5536
Castellani, Gastone https://orcid.org/0000-0003-4892-925X
Ossenkoppele, Gert J.
Hernández-Rivas, Jesus María https://orcid.org/0000-0002-9661-9371
Bullinger, Lars https://orcid.org/0000-0002-5890-5510
Heuser, Michael https://orcid.org/0000-0001-5318-9044
- License Information
-
More Information
Article History
Received: 20 October 2025
Revised: 15 December 2025
Accepted: 27 January 2026
First Online: 9 February 2026
Competing interests
: MS: honoraria from Novartis, Celgene, AOP Orphan, AbbVie. KHM: honoraria from AbbVie, Bristol Myers Squibb, Celgene, Janssen, Novartis, Pfizer, Otsuka; research funding from AbbVie. ATT: Consultancy for Maat Pharma, CSL Behring, Biomarin, Pfizer and Onkowissen. Educational presentation for Amgen. Travel reimbursements by Neovii and Novartis. Research funding by Neovii and Ground Truth Labs. GO: honoraria from Abbvie, Jazz Pharmaceuticals, Astellas, Gilead, Bristol Myers Squibb, Servier, Roche. BJPH: honoraria from Pfizer, Bristol Myers Squibb, Novartis. FT: Advisory/ consultancy for BMS, Novartis, AbbVie, Menarini, Rigel, Agile and honoraria from AbbVie, Astellas and Jazz. F.H.H. served as an advisor for Novartis, CTI, BMS, Janssen, Abbvie, GSK, Merck and AOP and received research funding from Novartis, Celgene/BMS and CTI. KD: honoraria from Novartis, Jazz Pharmaceuticals, Abbvie; has participated in Ad-Boards from Novartis, Bristol Myers Squibb, Jazz Pharmaceuticals, Abbvie; research funding from Novartis, Astellas, Agios, Bristol Myers Squibb, Kronos. TH: current employment at Munich Leukemia Laboratory, with part ownership. HD: Advisory role for AbbVie, Agios, Amgen, Astellas, AstraZeneca, BERLIN-CHEMIE, Bristol Myers Squibb, Celgene, GEMoaB, Gilead Sciences, Janssen, Jazz Pharmaceuticals, Novartis, Syndax; research funding from AbbVie, Agios, Amgen, Astellas, Bristol Myers Squibb, Jazz Pharmaceuticals, Kronos-Bio, Novartis. JMHR: honoraria from Bristol Myers Squibb, Pfizer, Amgen, Celgene, GSK, Novartis; Advisory role for Bristol Myers Squibb, Pfizer, Amgen, Celgene, Novartis; research funding from GSK and Pfizer. LB: honoraria from AbbVie, Amgen, Astellas, Bristol Myers Squibb, Celgene, Daiichi Sankyo, Gilead, Hexal, Janssen, Jazz Pharmaceuticals, Menarini, Novartis, Otsuka, Pfizer, Roche, and Sanofi; research funding from Bayer, Jazz Pharmaceuticals. MH: honoraria from Astellas, Daiichi Sankyo, Janssen, Miltenyi, Otsuka, Qiagen, and Servier, paid consultancy for Abbvie, AvenCell, Ascentage Pharma, Bristol Myers Squibb, Janssen, Jazz Pharmaceuticals, LabDelbert, Novartis, Pfizer, and Servier, and research funding to his institution from Abbvie, Bayer Pharma AG, Jazz Pharmaceuticals, Glycostem, Karyopharm, PinotBio, Servier, and Toray.
